Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma

Table 1 Numbers and Percentages of ALK-Rearranged Cells in Tumors and in CTC of ALK-Positive Patients

Patient	Sex	Age (y/o)	Smoking status (y/o)	Adenocarcinoma subtype	Clinical stage	Tumor		CTCs by NanoVelcro			CTC number by CellSearch (7.5 ml)
Patient	Sex	Age (y/o)	Smoking status (y/o)	Adenocarcinoma subtype	Clinical stage	Biopsy origin	% of rearranged cells	Rearranged CTCs (per ml)	% of rearranged CTCs	Total CTCs (per ml)	CTC number by CellSearch (7.5 ml)
P1	F	51	2	Papillary	III	Pleura (MS)	43	6	35	17	46
P2	F	47	0	Mucinous	IV	Lung (PT)	38	5	39	13	23
P3	M	43	0	Papillary	III	Node (MS)	27	3	22	9	0
P4	M	68	15	Mucinous	IV	Pleura (MS)	57	27	87	31	71
P5	M	54	21	Papillary	IV	Bone (MS)	96	32	87	37	29
P6	M	69	41	Solid	IV	Node (MS)	86	21	70	30	41
P7	F	37	0	Mucinous	III	Node (MS)	41	7	47	15	51
P8	F	58	0	Solid	IV	Lung (PT)	47	17	90	19	19
P9	F	57	0	Solid	IV	Lung (PT)	37	21	75	28	51
P10	F	63	0	Mucinous	IV	Lung (PT)	82	36	84	43	27
P11	M	71	10	Mucinou	III	Pleura (MS)	31	9	43	21	33
P12	M	41	0	Mucinou	IV	Node (MS)	71	25	86	29	34
P13	F	82	0	Mucinou	IV	Brain (MS)	51	17	100	17	19
P14	F	35	0	Solid	III	Lung (PT)	19	3	33	8	0
P15	F	47	0	Solid	III	Lung (PT)	47	9	100	9	37
P16	M	49	0	Papillary	III	Node (MS)	49	3	50	6	48
P17	F	53	12	Mucinou	IV	Node (MS)	59	24	83	29	61
P18	F	49	1	Solid	IV	Lung (PT)	42	19	58	33	48
P19	F	67	0	Mucinou	III	Lung (PT)	36	8	47	17	31
P20	M	69	19	Solid	III	Node (MS)	38	10	48	21	29
P21	M	45	0	Solid	IV	Lung (PT)	79	28	76	37	51

ALK anaplastic lymphoma kinase, CTC circulating tumor cell, F female, M male, MS metastatic site, PT primary tumor

ISSN: 1479-5876